Sleep Apnea Related to COVID-19 Results

The ultrastructural morphology of the novel coronavirus 2019 (2019-nCoV) identified as the cause of a respiratory outbreak first discovered in Wuhan, China, is in a published by the Centers for Control and Prevention (CDC.) Illustration shown) in Atlanta, Georgia, USA, Jan. 29, 2020. Alissa Eckert, MS; Dan Higgins, MAM / CDC / Handout via REUTERS.

Register now for FREE unlimited access to Reuters.com

to register

Nov 10 (Reuters) – (This Nov 10 story corrects the heading and first point to show that sleep apnea, regardless of severity, was a risk factor for severe COVID-19)

Below is a summary of some recent studies on COVID-19. This includes research that warrants further studies to confirm the results and that has yet to be certified through peer review.

Sleep apnea related to severe COVID-19

Register now for FREE unlimited access to Reuters.com

to register

The risk of developing serious illness from COVID-19 is higher in people with obstructive sleep apnea and other breathing problems that cause oxygen levels to drop while they sleep, researchers say. They tracked 5,402 adults with these issues and found that about a third of them were eventually tested for the coronavirus. While periodic episodes of respiratory failure during sleep – which resulted in low oxygen levels or hypoxia – did not increase people’s likelihood of infection, sleep-related hypoxia increased the likelihood of infected patients being hospitalized or dying of COVID-19. Drs. Cinthya Pena Orbea and Reena Mehra from the Cleveland Clinic and colleagues reported at the JAMA Network Open on Wednesday. It’s not clear whether treatments that improve sleep apnea, such as CPAP machines, which force air into patients’ airways while they sleep, would also reduce the risk of severe COVID-19, Pena Orbea and Mehra said.

The body’s coronavirus memory can break off new infections

Health workers who did not test positive for COVID-19 despite high exposure to infected patients had T cells attacking a part of the virus that enables it to make copies of itself, according to a Nature published Wednesday Report. Researchers studying the 58 health workers found that their T cells were more responsive to a part of the virus called RTC, which is found in all human and animal coronaviruses, including all variants of SARS-CoV-2 is similar. They suspect that the T cells recognized the RTC because they “saw” it in other infections in other viruses. That makes the RTC a potentially good target for vaccines if further research confirms these results, study leaders Mala Maini and Leo Swadling, both from University College London, said in a joint email to Reuters. These data were collected during the first wave of the pandemic, they added. “We don’t know if this type of control is in circulation for other infectious variants.”

Vaccines induce neutralizing antibodies in breast milk

Infants could benefit from COVID-19 antibodies in breast milk, regardless of whether mothers acquired the antibodies through infection with SARS-CoV-2 or through vaccines, new evidence reported in JAMA Pediatrics on Wednesday. Researchers examined antibodies in breast milk samples from 47 mothers infected with the virus and 30 healthy mothers who had received vaccines from Moderna (MRNA.O) or Pfizer / BioNTech (PFE.N) (22UAy.DE). Antibodies from both groups were able to neutralize the active SARS-CoV-2 virus, and while antibodies from infection were detectable in milk for a longer period of time, antibody levels from the vaccination were “much more consistent,” said study leader Bridget Young from the University of Rochester School of Medicine and Dentistry in New York. So getting vaccinated after a COVID-19 infection is likely to be beneficial, as breast milk would then contain a variety of antibodies, she said. The researchers did not study the effect of the antibodies on the babies who consumed the milk.

Click for a Reuters graphic on Vaccines in Development.

Register now for FREE unlimited access to Reuters.com

to register

Reporting by Nancy Lapid; Adaptation by Tiffany Wu

Our Standards: The Thomson Reuters Trust Principles.

Leave a comment

Your email address will not be published. Required fields are marked *